Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00130884
Status:
COMPLETED
Last Update Posted:
2007-02-21
First Post:
2005-08-15
Brief Title:
Peroral Levosimendan in Chronic Heart Failure
Sponsor:
Orion Corporation Orion Pharma
Organization:
Orion Corporation Orion Pharma
Study Overview
Official Title:
Effects of Peroral Levosimendan in the Prevention of Further Hospitalisations in Patients With Chronic Heart Failure A Randomised Phase II Double-Blind Placebo-Controlled Multi-Centre Parallel-Group Study
Status:
COMPLETED
Status Verified Date:
2007-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will investigate the efficacy of oral levosimendan in patients with chronic New York Heart Association NYHA IIIb-IV heart failure HF using a composite end-point evaluating patient symptoms morbidity and mortality The patients are on treatment for at least 6 months
Detailed Description:
The patients are randomised to 3 groups higher or lower levosimendan dose group or placebo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None